J Yu1, W Mai2, Y Cui3, L Kong4. 1. Department of Head and Neck Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, 150081, China. 2. Department of Orthopedics, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, 150081, China. 3. Department of Radiation Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, 150081, China. 4. Department of Head and Neck Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, 150081, China. lingykongl@sina.com.
Abstract
PURPOSE: The aim of this study was to predict the key genes and pathways associated with papillary thyroid carcinoma (PTC). METHODS: Based on the microarray data of GSE3467 from Gene Expression Omnibus database, we identified the differentially expressed genes (DEGs) between 9 PTC samples and 9 normal controls. With the identified DEGs, functional enrichment analyses were performed. Additionally, a protein-protein interaction network was constructed to screened out some key gene nodes. These key nodes were then performed clustering analysis and pathway enrichment analysis. Furthermore, human PTC-associated network was constructed based on these key genes to investigate the potential relationships between genes and PTC. RESULTS: A total of 651 up-regulated and 692 down-regulated DEGs were identified in PTC samples compared with controls. The up-regulated DEGs, such as complement component 3 (C3), were mainly enriched in hsa04610:Complement and coagulation cascades. The down-regulated DEGs, including paired box 8 (PAX8), peroxisome proliferator-activated receptor gamma (PPARG), and cadherin 1, type 1 were found enriched in hsa05216:Thyroid cancer. Total 33 DEGs were considered as key genes, such as PAX8, PPARG and Jun proto-oncogene (JUN). Disease-associated network analysis found that 15 key genes such as JUN, PPARG and matrix metallopeptidase 9 (MMP9) were involved in this network. CONCLUSIONS: DEGs of C3, PPARG, PAX8, JUN and MMP9 were differentially expressed in PTC samples and may be used as potential biomarkers in the diagnosis and treatment of PTC. Additionally, pathways of complement and coagulation cascades and thyroid cancer may also play important roles in the development of PTC.
PURPOSE: The aim of this study was to predict the key genes and pathways associated with papillary thyroid carcinoma (PTC). METHODS: Based on the microarray data of GSE3467 from Gene Expression Omnibus database, we identified the differentially expressed genes (DEGs) between 9 PTC samples and 9 normal controls. With the identified DEGs, functional enrichment analyses were performed. Additionally, a protein-protein interaction network was constructed to screened out some key gene nodes. These key nodes were then performed clustering analysis and pathway enrichment analysis. Furthermore, human PTC-associated network was constructed based on these key genes to investigate the potential relationships between genes and PTC. RESULTS: A total of 651 up-regulated and 692 down-regulated DEGs were identified in PTC samples compared with controls. The up-regulated DEGs, such as complement component 3 (C3), were mainly enriched in hsa04610:Complement and coagulation cascades. The down-regulated DEGs, including paired box 8 (PAX8), peroxisome proliferator-activated receptor gamma (PPARG), and cadherin 1, type 1 were found enriched in hsa05216:Thyroid cancer. Total 33 DEGs were considered as key genes, such as PAX8, PPARG and Jun proto-oncogene (JUN). Disease-associated network analysis found that 15 key genes such as JUN, PPARG and matrix metallopeptidase 9 (MMP9) were involved in this network. CONCLUSIONS: DEGs of C3, PPARG, PAX8, JUN and MMP9 were differentially expressed in PTC samples and may be used as potential biomarkers in the diagnosis and treatment of PTC. Additionally, pathways of complement and coagulation cascades and thyroid cancer may also play important roles in the development of PTC.
Authors: Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle Journal: Proc Natl Acad Sci U S A Date: 2005-12-19 Impact factor: 11.205
Authors: Marije M Vleugel; Astrid E Greijer; Reinhard Bos; Elsken van der Wall; Paul J van Diest Journal: Hum Pathol Date: 2006-06 Impact factor: 3.466
Authors: A Campennì; R M Ruggeri; M Siracusa; S A Pignata; F Di Mauro; A Vento; F Trimarchi; S Baldari Journal: J Endocrinol Invest Date: 2018-03-16 Impact factor: 4.256
Authors: Dana Macejova; Jan Podoba; Lucia Toporova; Marianna Grigerova; Karol Kajo; Katarina Machalekova; Julius Brtko Journal: Oncol Lett Date: 2019-08-22 Impact factor: 2.967